Report cover image

Recombinant Proteins Market Size, Share & Trends Analysis By Product, By Application, By End-User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Publisher SPER Market Research Pvt. Ltd.
Published Mar 16, 2022
Length 236 Pages
SKU # SPER17053284

Description

Recombinant Proteins Market Size, Share & Trends Analysis By Product, By Application, By End-User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Global Recombinant Proteins Market projected to be worth USD 2.4 billion by 2030.

According to SPER Market Research, the recombinant proteins market estimated to reach USD 2.4 billion by 2030 with a CAGR of 10.2%. The fuels for the escalation of the market are; the collaboration of industry and academia, expiring of patents of biologic product, growing investments from the government in the pharmaceutical and bio pharmaceutical research and development.

Impact of COVID-19 on the Recombinant Proteins Market

The outbreak of COVID-19 gave an upsurge to the Recombinant Proteins Market; this is due to increase in research and development to reach out the cause of the infection. Companies with product for COVID-19 have a positive expansion.

Scope of the report:

Market size available for years 2019-2030

Base year considered

2021

Forecast period

2022-2030

Segments covered

By Product, By Application, By End-User, By Region

Geographies covered

North America, Europe, Asia Pacific, Latin America, Middle East, Africa

Companies Covered

Abcam plc, Abnova Corporation, ACRO Biosystems, Aviva Systems Biology Corporation, Biolegend, Bio-Rad Laboratories, Inc. , Biotech Corporation, BPS Bioscience, Inc., CellGenix GmbH, Enzo Life Sciences, Inc., GenScript, Icosagen AS, Merck KGaA, Miltenyi Biotech, Neuromics, PeproTech, Inc., ProSpec TechnoGene Ltd., Proteintech Group, Inc., ProteoGenix, R&D Systems, RayBiotech Inc, RICHCORE LIFESCIENCES PVT LTD, Sino Biological Inc., STEMCELL Technologies Inc, StressMarq Biosciences Inc, Thermo Fisher Scientific, Inc., United States Biological.

Drivers: increasing government funding and growing Research & Development costs in pharmaceutical & biotechnology companies

Government funding, growing pharmaceutical and biopharmaceuticals research and development are the key factors that drive the escalation of the market.

Restraints: declining price of recombinant Protein

Due to concentration of various market players in the production of recombinant Protein with no varying price; this lead to resist the escalation of the market.

Opportunity: Emerging Economies

Emerging Economies, like Asia Pacific is projected to tender huge opportunities for the players in this market; this is due to rising prevalence of infectious chronic disease, multiple healthcare sector, growing government funding in the research and development of the advanced techniques in proteomic and genomic research, increasing geriatric population, friendly regulatory policies.

Global Recombinant Proteins Market, By Product:

Based on the Product, Global Recombinant Proteins Market is segmented as; Adhesion Molecules and Receptors, Growth Factors and Chemokines, Immune Response Proteins, Kinase Proteins, Membrane Proteins, Recombinant Metabolic Enzymes, Regulatory Proteins, Structural Proteins, Other Recombinant Proteins.

Global Recombinant Proteins Market, By Application:

Based on the Application, Global Recombinant Proteins Market is segmented as; Drug Discovery & Development (Biologics, Cell & Gene Therapy, Vaccines), Biopharmaceutical Production, Biotechnology Research, Academic Research Studies, Other Applications (diagnostics, forensic, and cosmetology applications).

Global Recombinant Proteins Market, By End-User:

Based on the End-User, Global Recombinant Proteins Market is segmented as; Academic Research Institutes, Biotechnology Companies, Contract Research Organizations, Pharmaceutical & Biopharmaceutical Companies, Other End Users [diagnostic centers, laboratories (hospital-attached laboratories (HALs) and independent diagnostic laboratories), forensic laboratories, and the cosmetic industry].

Global Recombinant Proteins Market, By Region:

North America owns the prime share of the market; and this is due to the presence of top market players, government funding, growing prevalence of infectious and chronic diseases, growing research and development.

Table of Contents

236 Pages
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Recombinant Proteins Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Global Recombinant Proteins Market, By Product, 2019-2030 (USD Million)
6.1. Adhesion Molecules and Receptors
6.2. Growth Factors and Chemokines
6.3. Immune Response Proteins
6.4. Kinase Proteins
6.5. Membrane Proteins
6.6. Recombinant Metabolic Enzymes
6.7. Regulatory Proteins
6.8. Structural Proteins
6.9. Other Recombinant Proteins
7. Global Recombinant Proteins Market, By Application, 2019-2030 (USD Million)
7.1. Drug Discovery & Development
7.1.1. Biologics
7.1.2. Cell & Gene Therapy
7.1.3. Vaccines
7.2. Biopharmaceutical Production
7.3. Biotechnology Research
7.4. Academic Research Studies
7.5. Other Applications (diagnostics, forensic, and cosmetology applications)
8. Global Recombinant Proteins Market, By End-User, 2019-2030 (USD Million)
8.1. Academic Research Institutes
8.2. Biotechnology Companies
8.3. Contract Research Organizations
8.4. Pharmaceutical & Biopharmaceutical Companies
8.5. Other End Users [diagnostic centers, laboratories (hospital-attached laboratories (HALs) and independent diagnostic laboratories), forensic laboratories, and the cosmetic industry]
9. Global Recombinant Proteins Market, By Region, 2019-2030 (USD Million)
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific
9.4. South America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America
9.5. Middle East & Africa
9.5.1. Kingdom of Saudi Arabia
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa
10. Company Profiles
10.1. Abcam plc
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments
10.2. Abnova Corporation
10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments
10.3. ACRO Biosystems
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. Aviva Systems Biology Corporation
10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments
10.5. Biolegend
10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments
10.6. Bio-Rad Laboratories, Inc.
10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments
10.7. Biotech Corporation
10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments
10.8. BPS Bioscience, Inc.
10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments
10.9. CellGenix GmbH
10.9.1. Company details
10.9.2. Financial outlook
10.9.3. Product summary
10.9.4. Recent developments
10.10. Enzo Life Sciences, Inc.
10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments
10.11. GenScript
10.11.1 Company details
10.11.2 Financial outlook
10.11.3 Product summary
10.11.4 Recent developments
10.12. Icosagen AS
10.12.1. Company details
10.12.2. Financial outlook
10.12.3. Product summary
10.12.4. Recent developments
10.13. Merck KGaA
10.13.1. Company details
10.13.2. Financial outlook
10.13.3. Product summary
10.13.4. Recent developments
10.14. Miltenyi Biotech
10.14.1. Company details
10.14.2. Financial outlook
10.14.3. Product summary
10.14.4. Recent developments
10.15. Neuromics
10.15.1. Company details
10.15.2. Financial outlook
10.15.3. Product summary
10.15.4. Recent developments
10.16. PeproTech, Inc.
10.16.1. Company details
10.16.2. Financial outlook
10.16.3. Product summary
10.16.4. Recent developments
10.17. ProSpec TechnoGene Ltd.
10.17.1. Company details
10.17.2. Financial outlook
10.17.3. Product summary
10.17.4. Recent developments
10.18. Proteintech Group, Inc.
10.18.1. Company details
10.18.2. Financial outlook
10.18.3. Product summary
10.18.4. Recent developments
10.19. ProteoGenix
10.19.1. Company details
10.19.2. Financial outlook
10.19.3. Product summary
10.19.4. Recent developments
10.20. R&D Systems
10.20.1. Company details
10.20.2. Financial outlook
10.20.3. Product summary
10.20.4. Recent developments
10.21. RayBiotech Inc.
10.21.1. Company details
10.21.2. Financial outlook
10.21.3. Product summary
10.21.4. Recent developments
10.22. Richcore Lifesciences Pvt Ltd
10.22.1. Company details
10.22.2. Financial outlook
10.22.3. Product summary
10.22.4. Recent developments
10.23. Sino Biological Inc.
10.23.1. Company details
10.23.2. Financial outlook
10.23.3. Product summary
10.23.4. Recent developments
10.24. STEMCELL Technologies Inc
10.24.1. Company details
10.24.2. Financial outlook
10.24.3. Product summary
10.24.4. Recent developments
10.25. StressMarq Biosciences Inc
10.25.1. Company details
10.25.2. Financial outlook
10.25.3. Product summary
10.25.4. Recent developments
10.26. Thermo Fisher Scientific, Inc.
10.26.1. Company details
10.26.2. Financial outlook
10.26.3. Product summary
10.26.4. Recent developments
10.27. United States Biological
10.27.1. Company details
10.27.2. Financial outlook
10.27.3. Product summary
10.27.4. Recent developments

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us